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Introduction
Fas, also called CD95 or APO-1, which belongs to
TNF Superfamily of membrane death receptors,
induces cell death by binding with FasL (Fas Ligand).
Fas was the first death receptor to be described as an
apoptosis-inducing receptor [1]. FasL (CD95L, APO-
1L) is expressed on activated T cells and NK cells, and
mediates immune responses [2]. Membrane-bound
FasL induces apoptotic cell death of Fas-positive cells
[3]. FasL overexpression is involved in the formation
of immune privilege. The immune-privileged sites
such as the anterior chamber of the eye, the Sertoli
cells in the testis, the brain, the ovary and the uterus
and placenta during pregnancy, constitutively express
high amounts of FasL and thus can protect themselves
from immune reactions [4]. FasL, expressed locally
and released from cells of those organs, where sys-
temic immunity is poorly induced, immediately kills
infiltrating immunocompetent cells and induces apop-
tosis of Fas-positive activated T cells that infiltrate into
the tissues [4,5]. Fas-mediated apoptosis is an impor-
tant mechanism in cell-mediated immune response [1].
As shown by previous investigations, Fas and its
ligand, FasL, are involved in the elimination of acti-
vated lymphocytes by apoptosis, to down-regulate
immune responses. Thereby the Fas/FasL system plays
a crucial role in the maintaining of the immune home-
ostasis, and also in the regulation of immune response
against tumours [6]. However, high FasL expression
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Abstract. Fas and FasL interaction induces apoptotic cell death. In immunocompetent cells it plays a crucial role in the
effector functions of the cells and in the regulation of host immune response. In tumours (e.g. melanoma), FasL expression
possibly counteracts the Fas-positive effector T cells that infiltrate into tumours, and consequently the Fas/FasL interaction
can contribute to the escape of tumour cells from the systemic immune response. In this study we examined differences in
Fas and FasL expression on cells from the hamster melanotic melanoma line (Ma) and a more aggressive amelanotic
melanoma line (Ab). We also tried to find out whether the Fas/FasL expression induces an ability to undergo spontaneous
apoptosis in these two transplantable melanoma lines. Our previous studies have shown that cells of the Ma line have a high-
er ability to undergo spontaneous apoptosis than cells of the Ab line. Isolated transplantable melanoma cells were incubat-
ed for 4 and 24 hours and after that time the expression of Fas and FasL was estimated by flow cytometry. The results show
that there was no Fas expression, although  FasL was detected on both melanoma cell lines. Therefore the data reported by
other authors indicate that a lack or a low level of Fas expression and an ectopic expression of FasL on melanoma cells can
be an escape mechanism of the tumour, to avoid host immune responses. The content of FasL-positive melanotic melanoma
cells was higher than in amelanotic melanoma cells and increased with the prolongation of the incubation time. FasL expres-
sion on amelanotic melanoma cells was detected after 24 hours at a level similar to that on melanotic melanoma cells after
4 hours incubation time. FasL expression on melanoma cells can induce apoptosis in cytotoxic T lymphocytes and NK cells
which are responsible for tumour cells elimination. The results obtained suggest that the Fas/FasL system does not play any
significant role in spontaneous apoptosis of two melanoma cell lines. But these results may indicate the presence of immune
privilege of tumour cells with FasL expression. 
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has been consistently observed in different types of
human tumours, also in melanomas. The loss of cell
surface Fas expression has been described for
melanomas, breast and oesophageal tumours,
leukemia, lymphomas [7,8,9]. On the other hand, it has
been reported that a variety of malignant tumours,
including: carcinomas of the colon, breast, ovary, uri-
nary bladder, lung, head and neck, melanoma, astrocy-
toma, show an increased FasL expression [7,10,11]. In
the case of melanoma, an increased FasL expression is
correlated with aggressiveness and bad prognosis. Due
to FasL up-regulation and Fas down-regulation, malig-
nant tumours could evade immune control via induc-
tion of apoptosis of effector immune cells, like cyto-
toxic T cells and NK cells, in a process that has been
called 'tumour counterattack' [4,12,13]. 
Apoptosis plays an important role in the regulation
of the number of cells and is controlled by a variety of
intracellular and extracellular signals: via receptors
(extrinsic pathway) and mitochondria (intrinsic path-
way) [14,15,16]. Ligands bind with membrane-bound
death receptors and activate caspases. Apoptotic sig-
nalling appears when the Fas/FasL system binds to the
Fas-associated death domain (FADD) in the cyto-
plasm, with a subsequent activation of caspase 8, and
initiates the executionary phase of apoptosis. The sig-
nal may be delivered to mitochondria and is amplified
due to the release of proapoptotic molecules such as
cytochrome c [1,14]. This signal transduction pathway
leads to apoptotic cell death.
Some invasive tumours, like melanoma, character-
ized by a Fas negative/FasL positive phenotype may
be connected with a worse prognosis [17]. Those
results inclined us to investigate the Fas/FasL system
and its role in cells of two lines of hamster trans-
plantable melanomas: melanotic and amelanotic, of
common origin but differing in many biological fea-
tures.
Thus, the aim of the present investigation was to
analyse the expression of Fas and FasL on cells of two
transplantable melanoma lines and possible changes
which might be associated with a spontaneous alter-
ation of the native melanotic melanoma form into ame-
lanotic one, accompanied by tumor progression (with
a higher growth rate and shorter animal survival time).
Our previous observations concerning the ability of
melanoma cells to undergo spontaneous apoptosis
[18,19,20] have shown that melanotic melanoma cells
(Ma) have a higher ability to undergo spontaneous
apoptosis than amelanotic melanoma cells (Ab). In the
present study we would like to find a relationship
between the expression of the Fas/FasL system and the
ability of melanotic and amelanotic melanoma cells to
undergo spontaneous apoptosis and a possibility to use
the Fas/FasL death pathway for therapeutic strategies
for this highly malignant tumour. 
Materials and Methods
Animals. 3-4 months old male Syrian (golden) hamsters
Mesocricetus auratus Waterhouse, were purchased from the Cen-
tral Animal Facilities of Silesian Medical University (Katowice,
Poland). The experiments' procedures were approved by the Ani-
mal Ethics Committee of Medical University of Gdansk
(16/2007;18.06.2007) and confirmed to the National Health and
Medical Research Council's guide for the care and use of laborato-
ry animals.
Transplantable melanomas. Cells for studies were isolated from
transplantable melanotic and amelanotic melanomas [21]. 
Melanotic melanoma line (Ma). The original transplantable
melanotic melanoma line derived from a spontaneous melanoma of
the skin which had appeared in a breed of golden hamsters in 1959. 
Amelanotic melanoma line (Ab) originated from the melanotic
form (Ma) by a spontaneous alteration and had appeared in a
breed of golden hamsters in 1963. Both transplantable melanoma
lines were described by Bomirski in 1977 as melanotic (Ma) and
amelanotic (Ab) melanoma lines [22,23]. Loss of pigment in the
Ab line was accompanied by changes in many biological features
- faster tumour growth rate, shorter animal survival time, cell
ultrastructure changes and changes in antigenicity and immuno-
genicity [21,22]. Once established, these melanomas possessed a
considerable degree of phenotypic stability over decades of pas-
saging [21]. Since their discovery, each melanoma line is main-
tained in vivo by consecutive, subcutaneous transplantations of
tumour material every 21 (Ma) or 11 (Ab) days. At that time 2-3
animals were used for the experiments in each experimental
group of animals.
Isolation of melanotic and amelanotic melanoma cells.
Melanoma cells were isolated for each experiment from solid
tumours by mechanical dissociation of tissue. Then melanoma
cells were isolated by means of a mixture 9% Ficoll 400 (Pharma-
cia, Sweden) and 75% uropoline (Polpharma, Poland) in ratio 7.6:1
as described previously [19,24]. The suspension contained 95-98%
of viable cells (estimated by trypan blue test).
Incubation of cells. Isolated melanoma cells at the concentration
of 2×106/ml were incubated in  RPMI 1640 (culture medium;
Biomed, Poland) with 10% FCS (fetal calf serum; Gibco) and
antibiotics in 6-well plates (Corning) at 37°C, for 4 and 24 hours.
Detection of Fas and FasL expression by flow cytometry. After
incubation time cells were harvested, washed with PBS and
immunostained with: hamster anti-mouse Fas monoclonal anti-
body and mouse anti-mouse FasL monoclonal antibody conjugat-
ed with phycoerythrine (PE) (1 μg/106 cells; BD Pharmingen, CA,
USA). Cells were incubated for 40 minutes, in dark. Then, cells
were washed with PBS three times and the intensity of fluores-
cence was measured with the FACS Calibour (Becton Dickinson,
NJ, USA). 
The background isotype control of non-specific binding to the cells
was PE-labelled mouse IgG2b (BD Pharmingen, CA, USA). Ham-
ster splenocytes for Fas and hamster peritoneal macrophages for
FasL were used as a positive control. After gating out small-sized
(e.g. noncellular debris) object, fluorescence obtained from 10000
- 20000 cells per sample, were analysed with WinMDI 2.6 Soft-
ware (J. Trotter, The Scripps Institute, La Jolla, CA, USA) and
were shown as percentage of Fas- or FasL-positive cells.
Statistical analysis. Data expressed as mean ±SD were statistical-
ly estimated by the non-parametric Mann-Whitney U test using
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StatSoft, Inc. (2005) STATISTICA (data analysis software system),
version 7.1. www.statsoft.com. The value of p<0.05 was consid-
ered to represent a statistically significant difference. 
Results 
Fas expression on the transplantable melanoma
cell lines
The flow cytometric results of hamster transplantable
melanoma cells Fas antibody binding are shown in
Fig. 1.
Both, on melanotic melanoma (Ma) cells and on
amelanotic melanoma (Ab) cells, after 4 and 24 hours
Fas expression was not observed (Table 1). Only a few
melanotic and amelanotic melanoma cells (Table 1)
bound anti-Fas antibody in comparison with hamster
splenocytes - among which 42.5% were Fas-positive
(Fig. 1).
FasL expression on the transplantable
melanoma cell lines
The results of FasL antibody binding by examined
melanoma cells are shown in Fig. 2.
FasL was detected on both melanoma cell lines
(Table 1). In hamster peritoneal macrophages, used as
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Fig. 1. Expression of Fas on transplantable melanotic
(Ma) and amelanotic (Ab) melanoma cells. The plots
show results of one representative experiment of flow
cytometric detection of Fas-positive cells (a - area of Fas-
positive melanoma cells). Inserts show fluorescence lev-
els of isotype control. The percentages in the corner of
each plot show the positive cells among the population of
cells after elimination of background isotype control.
Hamster splenocytes were used as a positive control for
the Fas receptor.
a posistive control of FasL expression, 51.3% were
FasL-positive. A number of melanotic and amelanotic
melanoma cells with FasL expression increased with
the extension of incubation time. We observed signifi-
cant differences in a number of melanoma cells with
the FasL expression between melanotic line and more
aggressive amelanotic line. About 11.4% of the native
melanotic melanoma cells bound anti-FasL antibody
after 4 hours, and about 32.6% after 24 hours (Table 1;
Fig. 2). While among amelanotic melanoma cells only
1.0% showed FasL expression after 4 hours and this
number of cells increased to 12.9% after 24 hours
(Table 1; Fig. 2). Therefore, after 24 hours of incuba-
tion FasL appeared on a similar level like initially
melanotic melanoma cells had (Table 1). 
Observing a dynamics of the FasL expression on
cells of both melanoma lines, we could ascertain that
after 4 and 24 hours quantitatively number of melanot-
ic melanoma (Ma) cells with the FasL expression is
relatively greater in comparison with amelanotic
melanoma (Ab) cells. But, in case of amelanotic
melanoma (Ab) line, with more aggressive phenotype,
the observed increase in the FasL expression was
much more dynamic, because we observed 12-fold
increase after 24 hours, and in case of melanotic
melanoma (Ma) cells, the observed increase of the
FasL expression was only about 3-fold in comparison
with the 4-hour-culture. 
Discussion 
Melanoma is one of the most aggressive tumours, and
mortality caused by melanoma has been on the
increase. Molecular mechanisms of this problem are
still unknown and are the subject of many studies
[14,15,16]. One of those mechanisms is the Fas/FasL
system, which has been studied for many years
[1,2,25]. The Fas/FasL system induces cell death path-
way via receptors (extrinsic pathway). Many inducers
and inhibitors of this way of apoptosis have been
reported. It is well recognized that the Fas/FasL path-
way is involved in the apoptotic process in different
pathologies and in the cytotoxic effects of most
immuno- and chemotherapeutic agents [1,2,26,27].
The expression and function of the Fas receptor play
an important role in the maintaining of homeostasis.
Different types of tumour cells have been shown to
escape immune recognition by constitutive resistance
to Fas-mediated apoptosis [6,7,25]. Melanoma cells
are often characterized by reduced Fas expression
and/or death signalling function, rendering them resist-
ant to cell death mediated by FasL [3,17,27,28,29].
Due to a higher FasL expression, tumour cells can
induce apoptosis of immune cells [7,17]. A loss of Fas
signaling may occur in melanoma, and FasL upregula-
tion on these tumour cells probably occurs during
tumorigenesis [3]. In the case of metastasis, a higher
FasL expression on tumor cells could facilitate their
migration into tissues surrounding the tumour,
throughout the elimination of normal cells with Fas on
their surface [7]. 
The results of the present study indicate that cells of
two transplantable melanoma lines expressed Fas
receptor at a low level, without any differences
between the lines examined, so the Fas expression did
not change when the tumour altered from melanotic
into amelanotic melanoma line with a more aggressive
phenotype. After a longer incubation time, the number
of cells with FasL expression changed, and distinct dif-
ferences were observable between the melanoma lines.
The results for cells of both melanoma lines, obtained
after 4 hours of incubation, may indicate the contribu-
tion of the Fas/FasL system to the induction of sponta-
neous apoptosis, though only to an insignificant degree
(only a few per cent). So, we can say that apoptosis,
induced by the Fas/FasL system, does not play a key
role in transplantable melanoma cells [20,30], despite
the higher ability to undergo spontaneous apoptosis of
melanotic melanoma cells in comparison with amelan-
otic melanoma cells - more aggressive and with a
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Table 1. Percentage of Fas- and FasL-positive cells of two transplantable melanoma: melanotic (Ma) and amelanotic (Ab) lines. The val-
ues are means ±SD of 4 - 7 experiments for Fas and FasL expression. Statistical analysis by the Mann-Whitney U test: * statistically sig-
nificant increase of FasL-positive cells among melanotic melanoma cells in comparison with 4-hour-culture; p<0.05. **Statistically sig-
nificant increase of FasL-positive cells among amelanotic melanoma cells in comparison with 4-hour-culture; statistically significant
decrease of FasL-positive cells among amelanotic melanoma cells in comparison with melanotic melanoma cells; p<0.05. ***Statistical-
ly significant decrease of FasL-positive cells among amelanotic melanoma cells in comparison with melanotic melanoma cells; p<0.05.
lower ability to spontaneous apoptosis. Thus, we can
suggest that in both transplantable melanoma cell lines
the intrinsic pathway of apoptosis plays a more impor-
tant role than the extrinsic one [18,30]. 
But, both melanoma lines indicate a considerable
difference in the content of FasL-positive cells which
was lower  in the case of the more aggressive amelan-
otic line. It might be, as some other authors suggest
[4,31,32], caused by the shedding of FasL by amelan-
otic melanoma cells, a more aggressive and more
apoptosis-resistant transplantable melanoma line, to
avoid Fas/FasL-induced apoptosis. Wada et al. [33]
demonstrated that at high levels FasL triggered an
inflammatory response, but at a low level it enhanced
tumour growth. The same authors also suggested that
FasL expressed in tumours, even at relatively low lev-
els, is capable of killing tumour-infilrating lympho-
cytes. The above-mentioned observations of Wada A et
al. [33], seem to confirm a low FasL-positive cells
content in the more aggressive and faster growing
amelanotic melanoma line. Thus, a low FasL level may
help tumours escape the immune attack. The observed
significant differences in the dynamics of FasL expres-
sion on cells of both melanoma lines, attendant upon
spontaneous alternation of native melanotic melanoma
into amelanotic melanoma line with changed biologi-
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Fig. 2. Expression of FasL on transplantable melanotic
(Ma) and amelanotic (Ab) melanoma cells. The plots
show results of one representative experiment of flow
cytometric detection of FasL-positive cells (a - area of
FasL-positive melanoma cells). Inserts show fluorescence
levels of isotype control. The percentages in the corner of
each plot show the positive cells among the population of
cells after elimination of background isotype control.
Hamster peritoneal macrophages were used as a positive
control for the FasL ligand. 
cal properties, may suggest that melanoma cells could
evade immune control and induce apoptosis of effector
immune cells infiltrating the tumour.
Hahne et al. [7], as mentioned earlier, reported that
the FasL protein is present in melanoma, and may pro-
mote the evasion of antitumour immune responses.
However, little or no Fas was expressed by melanoma
cells in all patients they examined [7]. In contrast, the
majority of cells infiltrating the tumour mass were Fas-
positive. FasL-expressing melanoma cells (in vitro)
induce apoptosis of Fas-sensitive tumour-infiltrating
cells at a high rate. Therefore FasL plays an important
role in creating the immune privilege of melanoma [7].
No FasL was found in normal melanocytes of the skin,
indicating that FasL upregulation probably participates
in melanoma tumorigenesis [7]. These results are also
convergent with the results of other authors that human
and mouse melanoma cells express Fas ligand but
hardly any Fas, which may contribute to their immune
privilege [3,34]. Similar results were presented by
Soubrane et al. [28], who determinated the expression
of Fas and its ligand (FasL) on normal skin cells (mix-
ture of keratinocytes and melanocytes), and primary
and metastatic melanoma cells from patients, using
monoclonal antibodies and flow cytometric analysis of
labelled cells. They found that Fas expression was sig-
nificantly higher on normal control skin cells than on
cells from tumours, whatever the stage studied. But
they observed a significant increase of the FasL
expression on melanoma cells compared with normal
cells. Also Terheyden et al. [35] observed an increased
expression of FasL in cutaneous metastases as com-
pared with their primaries and concluded that FasL
expression correlates with the tumorigenicity of
melanoma cells, progression of disease and a worse
prognosis for the patient. 
Our results: a 12-fold increase of FasL-positive
amelanotic melanoma cells - with a higher immuno-
genicity, lower level of cell differentiation, higher
growth rate - in comparison with only about 3-fold
increase of FasL-positive cells among native melano-
tic melanoma, seem to suggest the occurrence of
immune privilege of amelanotic melanoma cells. The
increased dynamics of FasL expression on amelanotic
melanoma cells may indicate a possible counterattack
against activated immune effector cells such as T cells
and NK cells, which could account for the faster
growth of amelanotic melanoma cells. The results of
other authors, which indicate low Fas and high FasL
expression, in human [13] and animal [36]
melanomas,  jointly confirm our results for two ham-
ster transplantable melanoma cell lines - melanotic and
amelanotic. 
Tumour expression of FasL has been proposed to
aid in immune evasion through a 'Fas counterattack'
mechanism, but has also been described as a proin-
flammatory factor [33,37]. It is not yet fully under-
stood how FasL induces inflammation [38,39]. FasL
was originally described as a proapoptotic, anti-
inflammatory protein, but now it is known that FasL
can also activate the NFκB pathway and be pro-
inflammatory by mechanisms similar to those for TNF
[40,41]. 
Our previous results [42,43,44] indicate that two
melanoma lines differ in the secretion of some
cytokines, e.g. TNF, IL-10, which was higher in
melanotic melanoma cells. It might be connected with
differences in FasL expression level between amelan-
otic and melanotic melanoma lines. 
According to the results of this study and those of
other authors, it seems that the Fas/FasL system does
not play a key role in inducing spontaneous apoptosis
in two transplantable melanoma cell lines. Even if
FasL is detected on melanoma cells, its expression
does not necessarily predict susceptibility to death.
The results presented here support this hypothesis,
showing that loss of the Fas expression and/or function
and resistance to Fas-mediated apoptosis are frequent
both during melanoma development in situ and in
melanoma cell lines in vitro. The results obtained
could indicate that cells of two transplantable
melanoma lines may use Fas/FasL signalling to avoid
the immunological attack by increasing the FasL
expression and down-regulating the Fas receptor
expression. 
In conclusion, the findings that indicate changes in
the content of FasL-positive cells, attendant upon a
spontaneous alteration of transplantable melanoma,
show the importance of a complete analysis of FasL
expression by tumour cells, in order to fully describe
its biological function, and may help resolve the dis-
crepancies present in the literature regarding the
Fas/FasL system in melanoma. 
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